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Abstract
Objective: To assess the potential association of selected antiretrovirals (ARVs), including efavirenz, with suicidality.
Design: Retrospective analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS), by performing
a Multi-Item Gamma Poisson Shrinker (MGPS) disproportionality analysis.
Methods: MGPS disproportionality analysis, a technique to identify associations between drugs and adverse events, was
performed using cumulative data from the FAERS database collected up to August 2012. This method yields an Empirical
Bayesian Geometric Mean score and corresponding 90% confidence interval (EB05, EB95). EB05 scores ]2 were pre-defined as
a signal for a potential drug-event association. The FAERS database includes spontaneous adverse-event reports from consumers
and healthcare professionals. All FAERS reports of suicidality (including suicidal ideation, suicide attempt and completed suicide
or a composite of these) in patients taking efavirenz (as single agent or in fixed-dose combination), atazanavir, darunavir,
etravirine, nevirapine and raltegravir were identified. A number of parallel analyses were performed to assess the validity of the
methodology: fluoxetine and sertraline, antidepressants with a known association with suicidality, and raltegravir, an ARV with
rhabdomyolysis and myopathy listed as ‘‘uncommon’’ events in the US-prescribing information.
Results: A total of 29,856 adverse event reports were identified among patients receiving efavirenz, atazanavir, darunavir,
etravirine, nevirapine and raltegravir, of which 457 were reports of suicidality events. EB05 scores observed for the com-
posite suicidality term for efavirenz (EB050.796), and other ARVs (EB050.2790.368), were below the pre-defined
threshold. Fluoxetine and sertraline gave EB05 scores for suicidality 2. Raltegravir gave EB05 scores 2 for myopathy and
rhabdomyolysis.
Conclusions: The pre-determined threshold for signals for suicidality, including suicidal ideation, suicide attempt, completed
suicide and a composite suicidality endpoint, was not exceeded for efavirenz and other ARVs in this analysis. Efavirenz has been
associated with suicidality in clinical trials. Further studies that adjust for confounding factors are needed to better understand
any potential association with ARVs and suicidality.
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Introduction
Efavirenz is a non-nucleoside reverse transcriptase inhibitor
for the treatment of HIV infection in combination with other
antiretrovirals (ARVs). Rare but serious psychiatric adverse
events, including severe depression, suicidal ideation, non-
fatal suicide attempts and completed suicide, have been
reported in clinical trials and in post-marketing surveillance
among patients taking efavirenz [14]. Recently, a pooled
analysis of four AIDS Clinical Trial Group (ACTG) studies,
which included 5332 subjects, identified an increased risk
of suicidality in efavirenz-containing regimens compared to
regimens containing atazanavir, atazanavir/ritonavir, lopinavir/
ritonavir and zidovudine/lamivudine/abacavir [5].
The Food and Drug Administration Adverse Event Report-
ing System (FAERS, formerly AERS) is a database set up to
support the FDA’s post-marketing surveillance programme
by recording adverse events spontaneously reported by con-
sumers and healthcare professionals to the FDA or manu-
facturers [6]. As there is no measure of the total number of
patients exposed to a particular drug in a spontaneously
reported adverse event database, it is not possible to esti-
mate the rate of adverse events. Drug-event pair dispropor-
tionality analysis is a method to identify potential signals for
drug-associated adverse events using spontaneous adverse
event reporting surveillance databases [79]. Disproportion-
ality analysis compares the frequency that a selected adverse
event is reported with a given drug, to the frequency it
is reported with other drugs. Simple methods for dispro-
portionality analysis can be utilized, but when the number
of events is small, large estimates with wide confidence
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intervals can lead to many false-positive reporting rates
for very rare events [10,11]. A well-established technique to
minimize false-positive reporting rates is Multi-Item Gamma
Poisson Shrinker (MGPS) disproportionality analysis, which
applies a Bayesian shrinkage estimator to the relative
reporting ratio (RRR; the ratio of the observed frequency
to the expected frequency), to give smaller risk estimates
with narrower confidence intervals, even when event counts
are small [10,11].
The aim of this analysis was to assess the potential
association of selected ARVs, including efavirenz, with suicid-
ality by performing an MGPS disproportionality analysis of
the FAERS database.
Methods
Search of FAERS database
The analysis was performed using all cumulative data
available from the FAERS database collected from 1968 up
to 27 August 2012. The drugs of interest for the analysis,
selected for common use and mechanism of action, were
efavirenz and other ARVs, atazanavir, darunavir, etravirine,
nevirapine and raltegravir. For efavirenz, the records identi-
fied included those in which efavirenz was administered
alone or as part of the fixed-dose combination product
containing efavirenz, emtricitabine and tenofovir disoproxil
fumarate.
The Medical Dictionary for Regulatory Activities (MedDRA
version 15.0) preferred terms selected for identification of
adverse events were ‘‘suicidal ideation,’’ ‘‘suicide attempt’’
and ‘‘completed suicide’’ to match as closely as possible the
methods used in the ACTG-pooled analysis [5]. An additional
analysis was performed using a composite suicidality end-
point in which all reports associated with ‘‘suicidal ideation,’’
‘‘suicide attempt’’ or ‘‘completed suicide’’ were combined.
The individual term analysis provides the total number of
suicidality events reported, whereas the composite term
generates unique ‘‘suicidality’’ reports per drug, as two
events of interest could be identified in the same report.
A number of parallel analyses were performed to assess
the validity of the methodology: fluoxetine and sertraline,
antidepressants with a known association with suicidality
[12], and a sensitivity analysis with raltegravir, an ARV with
rhabdomyolysis andmyopathy listed as ‘‘uncommon’’ (defined
as between 1% and 0.1%) events in the US-prescribing
information [1315].
Duplicate records were deleted using a removal algorithm
on retrieved reports. Because adverse event reports are
collected from different sources such as consumers, drug
manufacturers and investigators, multiple reports referring to
the same adverse events are not uncommon in FAERS [10].
In order to unmask the effects of duplicate reports on signal
scores, the proprietary database software Oracle performs
automated duplicate detection on FAERS data. The duplicate
detection process is organized in multiple stages, each stage
defining ‘‘duplicate groups’’ based on matching records.
Matching is performed by considering equivalence in demo-
graphic fields (same gender, same or nearby age values,
death date if present) and a combination of manufacturer,
drug and event information, including drug and/or event
start dates. The algorithm also considers the report source
(i.e. spontaneous versus literature or study) and adjusts the
criteria accordingly.
Statistical analyses
The measure of disproportionality was defined in terms
of the RRR of observed to expected frequencies of reports
mentioning both the selected drug (Y) and the selected
adverse event (X), where:
Observed countNumber of reports for event X with drug Y,
Expected count
¼ ðNumber of reports for event XÞðNumber of reports for drug YÞ
Total number of reports
and
RRR ¼ Observed count
Expected count
The expected frequency of a drug-event is typically calculated
under the assumption of independence between drug and
event distributions. Therefore, this measure of disproportion-
ality is viewed also as a measure of association. Dispropor-
tionality analysis was performed using the MGPS method.
MGPS is a Bayesian method that provides a robust estimate
of the disproportionality measure, RRR, which is referred to
as the Empirical Bayesian Geometric Mean (EBGM) and its
corresponding 90% confidence interval (EB05, EB95). EBGM
is an estimate of the ratio of observed to expected number
of drug-event reports. EB05 values indicate about a 5%
probability that the true value of RRR (i.e. observed/expected)
falls below it. EB95 values indicate about a 5% probability that
the true value of RRR (i.e. observed/expected) falls above it.
EB05 scores ]2 (at least two times greater than expected)
indicate a potential signal for a drug-event association [16,17].
This threshold identifies drug-event combinations that are
reported at least twice as often as all other drug-event
combinations and was selected to provide sensitivity for
the detection of potential rare drug-event combinations
[16,17].
Results
The FAERS database included 29,856 adverse event reports
among patients receiving efavirenz, atazanavir, darunavir,
etravirine, nevirapine and raltegravir, including 197 reports of
suicidal ideation, 182 suicide attempts and 78 completed
suicides (457 events in total).
Measures of disproportionality (EBGM, EB05 and EB95) for
efavirenz, other ARVs, fluoxetine and sertraline are provided
in Figure 1. Disproportionality scores (EB05) for suicidality
observed for efavirenz were below the threshold of 2.
Efavirenz EB05 scores for suicidal ideation, suicide attempt
and completed suicide were 0.737, 1.118 and 0.416, respec-
tively. Likewise, all other ARVs did not exceed the threshold
EB05 score for suicidal ideation (0.3770.711), suicide attempt
(0.2180.501) or completed suicide (0.0230.149). Analysis
of the composite suicidality term for efavirenz produced
an EB05 score of 0.796, which was also below the threshold,
as were scores for all other ARVs (0.2790.368).
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Fluoxetine and sertraline had EB05 scores ]2 for suicidal
ideation, suicide attempt and completed suicide (Figure 1).
Analysis of the composite suicidality term for fluoxetine and
sertraline produced EB05 scores of 4.48 and 2.66, respec-
tively (Figure 1). In the sensitivity analysis for myopathy
and rhabdomyolysis, raltegravir gave EB05 scores of 2.334
and 2.333, respectively.
Conclusions
In this analysis, the level of disproportionality did not exceed
the pre-determined threshold of two for suicidality among
patients receiving efavirenz, or other ARVs. A potential signal
for suicidality was identified for the two SSRIs. Furthermore,
our analysis was sensitive enough to detect a potential signal
for uncommon adverse events with raltegravir. This is the first
analysis performed using a real-world dataset to assess the
association of efavirenz, or other ARVs, with suicidality.
Serious psychiatric adverse experiences have been reported
in patients treated with efavirenz in clinical trials [1,5].
In controlled trials, the frequency (regardless of causality)
of specific serious psychiatric events among patients who
received efavirenz versus control regimens were severe
depression (2.4% vs. 0.9%), suicidal ideation (0.7% vs. 0.3%),
non-fatal suicide attempts (0.5% vs. 0), aggressive behaviour
(0.4% vs. 0.5%), paranoid reactions (0.4% vs. 0.3%) and manic
reactions (0.2% vs. 0.3%) [1]. While an association of psy-
chiatric adverse events with EFV has been reported, the
relative magnitude of this risk compared to other ARVs is
less clear. The recently reported pooled analysis of four ACTG
studies reported a two-fold increase in risk of suicidality
with efavirenz-containing regimens [5]. However, the ACTG
analysis was retrospective using pooled data from four studies,
three of which were open label and none of which included
recognized psychiatric measures of suicidality or depression
[5]; limitations that also apply to the current FAERS analysis.
Patients tend to underreport psychiatric illness [18,19],
and healthcare providers do not systematically screen patients
for symptoms of psychiatric illnesses, which will impact
assessments in both clinical trials as well as observational
approaches [20,21]. Furthermore, warnings of suicide risk
have been reported in the efavirenz US package insert since
1998 [1], which may have led to ascertainment bias and/or
over- or underreporting in our FAERS analysis. Patients may
seek treatment for low mood or suicide ideation with non-
HIV physicians (who may be less aware of the label warning),
thus potentially further contributing to underreporting.
Channelling bias is also likely since providers who are aware
of the label warning would be expected to avoid prescrip-
tion of efavirenz in patients with a known history of mental
health problems.
The FAERS database was selected for this analysis based on
it being a large publicly accessible database from a hetero-
geneous patient population. However, there are a number of
established limitations to these data. For example, because
the database primarily includes spontaneous or voluntary
reports of adverse events, these records can be of vary-
ing quality and it is known that events are underreported
[10]. Reporting patterns may be influenced by marketing
and publicity about specific adverse events; the so-called
‘‘notoriety effect’’ [22,10]. The number of treated patients is
not known, so reporting rates cannot be calculated. It should
also be noted that while disproportionality analysis can
identify signals for potential correlations between drugs and
adverse events, it can neither determine whether there is a
Figure 1. MGPS signal scores of drug-event pairs for a) suicide ideation, b) suicide attempt, c) completed suicide and d) combined suicidality
terms. EBGM, Empirical Bayesian Geometric Mean; EB05, lower limit of the EBGM 90% confidence interval; EB95, EBGM upper limit of the
EBGM 90% confidence interval; nnumber of reports.
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direct cause-and-effect relationship nor quantify risk. The
failure of efavirenz to exceed the pre-determined threshold
for suicidality in this analysis must not be misinterpreted
as an absence of association, given the limitations of these
methods.
The results presented here were derived from spontaneous
reports based on actual clinical experience and hence they
complement those derived from randomized controlled
clinical trials. Clinical trials have previously identified an
increased risk of depression and suicidality with efavirenz
treatment [1,5]. The association between efavirenz use and
suicidality, as reflected in the product labelling warning,
should be kept in mind when making treatment decisions.
The risk of depression and suicidality among persons diag-
nosed with HIV infection indicates that, irrespective of ARV
therapy choice, psychiatric screening and counselling are
important aspects of clinical management [23]. Future studies
of experiences in randomized clinical trials or in routine clinical
practice would further elucidate any potential associations
between efavirenz use and suicidality.
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